NCT07621640Not yet recruiting
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET/CT and Cold Stimulation Protocol
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET/CT imaging before and after 24 weeks of treatment. Prior to each PET/CT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 20 May 2026
- Start date
- Jun 2026
- Primary completion date
- Feb 2028
- Lead sponsor
- Hallym University
- Diseases
- Obesity
- NCT number
- NCT07621640
What you commit to
- Study type: Interventional
- Planned participants: 80
- From Jun 2026 to the primary completion date, Feb 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents
- Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants)
Other illness
- Diagnosis of type 1 or type 2 diabetes mellitus
- History of neck surgery or radiation therapy to the neck
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
- Severe psychiatric illness or cognitive impairment precluding informed consent
Lab values
- Active malignancy, severe renal disease (eGFR \<30 mL/min/1.73m²), severe hepatic disease, or other severe endocrine disorders
Other
- Pregnancy or breastfeeding
- Severe claustrophobia
Who the study is looking for
- Age 20-70 years at the time of enrollment
- Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)
- BMI ≥ 27 kg/m² with at least one weight-related comorbidity:
- Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication)
- Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication)
- Non-alcoholic fatty liver disease (NAFLD/MASLD, confirmed by imaging or ALT/AST ≥1.5× ULN)
- Obstructive sleep apnea (AHI ≥5/hr or clinically diagnosed)
- Established cardiovascular disease (CAD, stroke, PAD)
- Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg/m² (regardless of comorbidity)
- Ability and willingness to provide written informed consent
Age in the registry: 20 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hallym University Dongtan Sacred Heart Hospital Coordinator of this site? Confirm its status | Hwaseong-si | South Korea | Unknown status |
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.